Policy & Regulation
BlueRock Therapeutics receives Health Canada approval to start Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy
8 April 2021 -

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has received approval from Health Canada to start its 'Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease,' it was reported on Wednesday.

This is the first trial in Canada to assess pluripotent stem cell-derived dopaminergic neurons in subjects with Parkinson's disease. The company is enrolling 10 patients in the United States and Canada for the trial, with the Canadian trial site at University Health Network, a research and teaching hospital network located in Toronto, Ontario.

The Ph1 study's primary objective is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.

Login
Username:

Password:


Related Headlines

BenevolentAI announces baricitinib reduces deaths in hospitalised COVID-19 patients by 38%

Everest receives FDA approval for Trodelvy for the treatment of metastatic triple negative breast cancer

City of Hope Enters Licensing Agreements with CytoImmune Therapeutics to Develop Portfolio of Chimeric Antigen Receptor-Natural Killer Therapies

Celcuity Inks Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer

Bristol Myers Squibb's Opdivo plus Chemotherapy and Opdivo plus Yervoy Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration

LUCA Science Opens New Subsidiary in the UK, Expands Collaboration with the University of Oxford on the Development of Novel Mitochondrial Therapeutics

UK researchers to study long-term impacts of COVID-19 lung damage

Open Medicine Foundation leads international study of COVID's conversion to ME/CFS to avert second pandemic

Alkermes signs clinical trial collaboration and supply agreement with MSD

BlueRock Therapeutics receives Health Canada approval to start Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy

AbbVie submits SKYRIZI approval applications to US FDA and European Medicines Agency

BeiGene awarded commercial manufacturing approval for state-of-the-art biologics facility in Guangzhou, China

Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories

Phase 1/2 Trial Initiated for Daiichi Sankyo's Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia